Publications

1. Assessment of 'established medical science and medical practice’ - a technical modification

   This report is a supplement to the existing Dutch assessment framework dating form 2015. It can be used to investigate whether an ...

   Report | 23-04-2019

2. Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults

   The National Health Care Institute carried out a marginal assessment whether the product brexpiprazole (Rxulti®) can be accepted ...

   Report | 16-04-2019

3. Pitolisant (Wakix®) for the treatment of narcolepsy in adults

   The National Health Care Institute  carried out a marginal assessment whether pitolisant (Wakix®) is interchangeable with a drug ...

   Report | 15-04-2019

4. Glycopyrronium bromide (Sialanar®) for the symptomatic treatment of severe sialorrhoea

   The National Health Care Institute carried out an assessment whether the product glycopyrronium bromide (Sialanar®) is ...

   Report | 09-04-2019

5. Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions

   The National Health Care Institute carried out an assessment whether the specific conditions for tolvaptan (Jinarc ®) can be ...

   Report | 02-04-2019

6. Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lung cancer

   The National Health Care Institute has completed its assessment of durvalumab (Imfinzi®) as monotherapy for the treatment of ...

   Report | 01-04-2019

7. Amendment of the conditional inclusion of the medicine Fingolimod (Gilenya®) for the treatment of relapsing remitting multiple sclerosis (RRMS)

   Zorginstituut Nederland carried out an assessment in relation to extending the specific conditions for the medicinal  product ...

   Report | 25-03-2019

8. Abemaciclib (Verzenios®) for the treatment of metastatic breast cancer

   The National Health Care Institute has completed its assessment of abemaciclib (Verzenios®) for the treatment of metastatic ...

   Report | 07-03-2019

9. Axicabtagene ciloleucel (Yescarta®) for the treatment of adult patients with recurring or refractory diffuse large-cell B-cell lymphoma (DLBCL) and primary mediastinal large-cell B-cell lymphoma (PMBCL)

   The National Health Care Institute carried out an assessment of the medicinal product axicabtagene ciloleucel (axi-cel, ...

   Report | 07-03-2019

10. Tisagenlecleucel (Kymriah®) for the treatment of DLBCL

    The National Health Care Institute has completed its assessment of tisagenlecleucel (Kymriah®) for the treatment of DLBCL. Due to ...

    Report | 07-03-2019